Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:KMDA NASDAQ:MLTX NYSE:TRLV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.70+5.5%$20.03$16.36▼$48.45$1.57B-0.0419,227 shs10,878 shsKMDAKamada$7.36+1.4%$7.77$6.50▼$9.35$417.49M0.8440,824 shs50,098 shsMLTXMoonLake Immunotherapeutics$19.91+0.1%$18.21$5.95▼$62.75$1.46B1.041.23 million shs1.31 million shsTRLVTrulieve Cannabis$9.27+3.2%$0.00$3.50▼$13.28$1.78BN/A588,366 shs1.03 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+5.55%+3.33%-11.54%-26.08%-55.30%KMDAKamada+1.38%+2.36%-5.76%-11.75%-4.54%MLTXMoonLake Immunotherapeutics+0.05%-10.15%+3.81%+6.81%-58.10%TRLVTrulieve Cannabis+3.91%+0.75%+927,399,900.00%+927,399,900.00%+927,399,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.70+5.5%$20.03$16.36▼$48.45$1.57B-0.0419,227 shs10,878 shsKMDAKamada$7.36+1.4%$7.77$6.50▼$9.35$417.49M0.8440,824 shs50,098 shsMLTXMoonLake Immunotherapeutics$19.91+0.1%$18.21$5.95▼$62.75$1.46B1.041.23 million shs1.31 million shsTRLVTrulieve Cannabis$9.27+3.2%$0.00$3.50▼$13.28$1.78BN/A588,366 shs1.03 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+5.55%+3.33%-11.54%-26.08%-55.30%KMDAKamada+1.38%+2.36%-5.76%-11.75%-4.54%MLTXMoonLake Immunotherapeutics+0.05%-10.15%+3.81%+6.81%-58.10%TRLVTrulieve Cannabis+3.91%+0.75%+927,399,900.00%+927,399,900.00%+927,399,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.20Buy$46.43162.31% UpsideKMDAKamada 3.00Buy$12.0063.04% UpsideMLTXMoonLake Immunotherapeutics 2.38Hold$23.8519.77% UpsideTRLVTrulieve Cannabis 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest KMDA, MLTX, AAPG, and TRLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026KMDAKamada Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)6/18/2026TRLVTrulieve Cannabis Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/16/2026TRLVTrulieve Cannabis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (D-)6/15/2026AAPGAscentage Pharma Group International BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.006/10/2026AAPGAscentage Pharma Group International Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026AAPGAscentage Pharma Group International B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/9/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/8/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/15/2026KMDAKamada Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/12/2026MLTXMoonLake Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/12/2026MLTXMoonLake Immunotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $30.00(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$574.12M2.88N/AN/A$2.04 per share8.68KMDAKamada$180.46M2.35$0.62 per share11.89$4.68 per share1.57MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/ATRLVTrulieve Cannabis$1.17B1.52N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$177.71MN/AN/AN/AN/AN/AN/AN/AN/AKMDAKamada$20.20M$0.3521.0312.070.6711.21%7.73%5.41%8/12/2026 (Estimated)MLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)TRLVTrulieve CannabisN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest KMDA, MLTX, AAPG, and TRLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026KMDAKamada$0.12$0.07-$0.05$0.07$46.72 million$45.24 million5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AKMDAKamada$0.192.58%N/A54.29%N/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ATRLVTrulieve CannabisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International0.571.791.77KMDAKamadaN/A3.331.90MLTXMoonLake Immunotherapeutics0.398.608.60TRLVTrulieve CannabisN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AKMDAKamada20.38%MLTXMoonLake Immunotherapeutics93.85%TRLVTrulieve CannabisN/AInsider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AKMDAKamada36.10%MLTXMoonLake Immunotherapeutics12.05%TRLVTrulieve CannabisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.39 millionN/AN/AKMDAKamada36057.51 million36.75 millionOptionableMLTXMoonLake Immunotherapeutics273.61 million64.74 millionOptionableTRLVTrulieve Cannabis9,000192.31 millionN/AN/AKMDA, MLTX, AAPG, and TRLV HeadlinesRecent News About These CompaniesKim Rivers Sells 136,811 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 28 at 5:43 AM | americanbankingnews.comTrulieve CEO Sells $1.2 Million in Stock as Shares Jump 148% in One YearJune 27 at 11:51 AM | fool.comTrulieve Cannabis (NYSE:TRLV) CEO Sells 136,811 SharesJune 27 at 5:51 AM | insidertrades.comKim Rivers Sells 380,000 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 27 at 5:16 AM | americanbankingnews.comKim Rivers Sells 300,000 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 27 at 5:16 AM | americanbankingnews.comKim Rivers Sells 400,000 Shares of Trulieve Cannabis (NYSE:TRLV) StockJune 27 at 5:16 AM | americanbankingnews.comPromising Cannabis Stocks To Follow Today - June 26thJune 27 at 4:39 AM | americanbankingnews.comTrulieve Announces Planned Termination of Executive Automatic Securities Disposition PlanJune 26, 2026 | prnewswire.comTRLV PE / PEG RatioJune 26, 2026 | seekingalpha.comInsider Selling: Trulieve Cannabis (NYSE:TRLV) CEO Sells $2,451,000.00 in StockJune 26, 2026 | insidertrades.comBest Cannabis Stocks Worth Watching - June 25thJune 26, 2026 | americanbankingnews.comTop Cannabis Stocks To Follow Now - June 24thJune 25, 2026 | americanbankingnews.comTRLV Trulieve Cannabis Corp.June 24, 2026 | seekingalpha.comCannabis Stocks To Follow Now - June 23rdJune 24, 2026 | americanbankingnews.comCannabis Stocks To Watch Today - June 22ndJune 23, 2026 | americanbankingnews.comTrulieve Cannabis (NYSE:TRLV) CEO Kim Rivers Sells 139,846 Shares of StockJune 23, 2026 | americanbankingnews.comTrulieve Cannabis (NYSE:TRLV) CEO Kim Rivers Sells 204,815 Shares of StockJune 23, 2026 | americanbankingnews.comTrulieve Cannabis (NYSE:TRLV) CEO Kim Rivers Sells 137,535 SharesJune 23, 2026 | americanbankingnews.comTrulieve Cannabis (NYSE:TRLV) CEO Sells $1,287,327.60 in StockJune 23, 2026 | insidertrades.comCannabis Stocks To Follow Today - June 19thJune 20, 2026 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKMDA, MLTX, AAPG, and TRLV Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$17.70 +0.93 (+5.55%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$17.70 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Kamada NASDAQ:KMDA$7.36 +0.10 (+1.38%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$7.37 +0.01 (+0.14%) As of 07:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.MoonLake Immunotherapeutics NASDAQ:MLTX$19.91 +0.01 (+0.05%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$20.18 +0.27 (+1.33%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Trulieve Cannabis NYSE:TRLV$9.27 +0.28 (+3.16%) Closing price 06/29/2026 03:59 PM EasternExtended Trading$9.37 +0.09 (+0.99%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
